CAD software for synthetic biology

01Overview and value chain#

Markers EC: EU AI Act general-purpose AI model obligations | OECD: Biotech and health | Regulator: FDA (USA), EMA (EU)

CAD software for synthetic biology applies the electronic-design-automation model from semiconductor chip design to genetic engineering: a biologist drafts a genetic construct in software, simulates how the design will behave, and generates an assembly protocol — all before committing to physical DNA synthesis. One platform’s patented machine-learning engine closes design-build-test-learn cycles ten times faster than random screening; another traces its core technology to Cello, a hybrid genetic-engineering and CAD platform originally built to program logic circuits directly into living cells. This is the digital design layer that sits upstream of both the commercial gene-synthesis foundries and the strain-engineering contract research organizations already covered on this site — the software drafts and simulates the construct, the foundry physically synthesizes it, and the CRO engineers the resulting strain, three distinct stages with three distinct vendor sets.

Key directions of CAD software for synthetic biology:

1. BioCAD/CAM platforms (BioCAD/CAM Platform): integrated design, simulation and assembly-protocol-generation software spanning the full design-build cycle for a genetic construct.
2. Design-build-test-learn automation (DBTL Automation): machine-learning and AI-agent tooling that closes the iterative cycle of designing, building, testing and refining a biological system faster than traditional screening.
3. Custom bespoke software development (Bespoke Synbio Software): software studios that embed with biotech companies to build internal design tools and workflow software rather than selling a one-size-fits-all product.
4. Genetic part and circuit simulation (Genetic Part Simulation): simulation engines that predict how a genetic circuit or part will behave in a target cell type before physical construction.

Sectoral value chain#

[genetic construct drafting] ──> [behavior simulation] ──> [assembly protocol generation] ──> [DBTL iteration]
                                                                        │
                                                          (physical synthesis handoff)
                                                                        │
                                                                        ▼
[optimized genetic design] <─── [experimental data feedback] <──┘

Value chain levels#

Cross-cutting technologies:

• BioCAD/CAM platform (BioCAD/CAM Platform): integrated software spanning genetic design, simulation and protocol generation.
• DBTL automation (Design-Build-Test-Learn Automation): ML/AI tooling accelerating iterative biological design cycles.
• Genetic part simulation (Genetic Part Simulation): predictive modeling of genetic circuit behavior before physical construction.

02US#

The US hosts the category’s most established and most heavily funded platforms, spanning an AI-native design-automation company, a bespoke software studio, and a CAD platform that originated as an academic logic-circuit-programming tool.

AI-accelerated DBTL platforms, bespoke embedded software studios, academic-to-commercial CAD lineage#

• TeselaGen (founded 2013): offers a BioCAD/CAM platform built around Synthetic Evolution®, a patented machine-learning engine the company states closes design-build-test-learn cycles ten times faster than random screening, alongside AI agents for library design and sequence optimization.
• Lattice Automation: a life-sciences software development studio that embeds with biotech teams to build custom internal design tools and workflow software rather than selling a single standardized product.
• Asimov’s CAD platform: co-founded in 2017 by the MIT professor behind Cello, a hybrid genetic-engineering/CAD system originally built to program logic-circuit behaviors into living cells, now offered as cloud-based software to design, simulate and optimize genetic systems across cell types.

03CN#

No confirmed Chinese commercial CAD-for-synthetic-biology vendor was found; Chinese activity in this space is concentrated in academic and student competition projects rather than standalone commercial software products.

academic and iGEM-competition tool development, no confirmed commercial vendor, broader synbio manufacturing capacity elsewhere#

• iGEM student competition tools: Chinese university teams have built award-winning genetic-circuit-design software (gene-circuit visual analytics, computer-aided synbio design tools) through the international iGEM synthetic-biology competition, demonstrating strong academic capability without a confirmed spinout into standalone commercial software.
• No confirmed specialist producer: searches for a mainland commercial BioCAD vendor returned only academic and open-source tools — left qualitative pending a real commercial candidate.
• Broader synbio capacity context: China’s substantial gene-synthesis and strain-engineering manufacturing capacity, covered elsewhere on this site, has not yet produced a confirmed standalone commercial design-software export comparable to the US platforms.

04EU#

The UK hosts a design-of-experiments software pioneer that pivoted from wet-lab synthetic biology into pure software, now validated by major pharmaceutical companies.

academic spinout to pure-software pivot, design-of-experiments automation, pharma-validated platform#

• Synthace (London, founded 2011): a University College London spinout that operated as a synthetic biology company before pivoting fully to software in 2017; its cloud-based Digital Experiment Platform automates design-of-experiments for complex biological processes, validated by AstraZeneca, GSK and Charles River.
• EU AI Act context: as CAD platforms increasingly embed machine-learning design-automation features, general-purpose AI model obligations under the EU AI Act are an emerging compliance consideration for European synbio-software vendors specifically.
• Recognition track record: Synthace was named a World Economic Forum Technology Pioneer in 2016 and a Gartner Cool Vendor in Life Sciences in 2018, external validation markers for a category where commercial traction can otherwise be hard to verify independently.

05Leading companies and research institutes#

06Tech stack and innovations#

The category borrows its core methodology from semiconductor electronic design automation, adapted to the added complexity of biological systems that don’t behave with silicon’s predictability.

1. Machine-learning-accelerated DBTL cycling (ML-Driven Design Iteration):
   • Patented ML engines learn from each round of experimental results to propose the next design iteration more efficiently than exhaustive or random screening, the core mechanism behind claimed order-of-magnitude speedups in design cycles.
   • AI agents increasingly handle specific sub-tasks within the cycle — library design, sequence optimization — rather than the platform being a single monolithic tool.
2. Genetic circuit and part simulation (Predictive Behavior Modeling):
   • Simulation engines predict how a genetic circuit will behave in a specific host cell type before physical construction, the capability that originated in academic logic-circuit-programming research before being commercialized.
   • Simulation accuracy depends on the quality and breadth of the underlying genetic-part behavior library, making part-library curation as important as the simulation algorithm itself.
3. Cloud-based design-of-experiments automation (DOE Platform Architecture):
   • Cloud platforms let a biologist design multivariate experiments, simulate them digitally, execute them on connected lab hardware and receive structured, AI-ready data — a no-code workflow bridging digital design and physical lab execution.
   • This architecture is what lets a platform originally built by synthetic biologists for their own use pivot into a standalone software product sold to other biotech companies.

07Value chains and production pipelines#

Industrial pipeline of a CAD-designed genetic construct#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Design intent capture   │ ───> │ 2. Construct drafting     │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Protocol generation    │ <─── │ 3. Behavior simulation    │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Physical synthesis     │ ───> │ 6. Data feedback & DBTL   │
│    handoff                 │      │    iteration               │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Design intent capture

The biologist specifies the desired function of the genetic construct — what behavior or output the design should produce in the target host cell.

Stage 2: Construct drafting

The software assembles a candidate genetic sequence or circuit from a library of characterized genetic parts, matching the specified design intent.

Stage 3: Behavior simulation

A simulation engine predicts how the drafted construct will behave in the target cell type, flagging likely failure modes before any physical synthesis is committed to.

Stage 4: Protocol generation

The platform generates the physical lab assembly protocol — a Gibson assembly, Golden Gate cloning or similar method — needed to build the finalized construct.

Stage 5: Physical synthesis handoff

The generated protocol and construct design are handed off to a gene-synthesis foundry or in-house lab for physical construction.

Stage 6: Data feedback and DBTL iteration

Experimental results from the physically built and tested construct are fed back into the design platform, closing the design-build-test-learn loop and informing the next design iteration.